Sepracoat

Sepracoat®

Surgery A liquid hyaluronic acid used to minimize postoperative adhesions by moistening exposed tissues during surgery. See Adhesion, Hyaluronic acid.
References in periodicals archive ?
Sepracoat is used during abdominal, pelvic, and thoracic surgeries to reduce post-operative adhesions caused by indirect trauma.
Genzyme General's Seprafilm(R) Approved for Cardiac Surgery in Europe
Sepracoat is designed to reduce adhesion formation that results from indirect trauma during surgery.
Genzyme General Focuses Business Strategy, Announces Financial Provisions
Tokyo, to market Genzyme General's Sepra product line, which includes Seprafilm, Sepracoat, and Sepragel(TM) bioresorbable gel.
In exchange for an undisclosed distribution rights fee and milestone payments, Kaken will receive co-marketing rights for Seprafilm and Sepracoat in Japan.
Genzyme General's Fourth Quarter EPS Was $.29 Before Acquisition Charges
Genzyme General plans to file an application in the second half of 1997 to market Sepracoat in Japan.
Sepracoat is intended to provide protection from incidental tissue damage caused by desiccation, manipulation, or contact with surgical instruments or materials.
Genzyme Partners with Japanese Firm to Market Sepra Product Line
It will allow Genzyme to move forward with market introduction plans in Europe, which include launching Sepracoat in Denmark, France, Germany, Italy, the Netherlands, Sweden, and the United Kingdom in the fourth quarter of this year.
Genzyme Receives CE Mark for Sepracoat
FDA notified the company it will expedite review of the Sepracoat PMA.
GENZYME TO ACQUIRE SURGICAL PRODUCTS COMPANY
The company anticipates that, in many kinds of surgery, Seprafilm and Sepracoat will be used together.
GENZYME GENERAL DIVISION EPS ROSE 23% IN FIRST QUARTER
Seprafilm is intended to reduce adhesion formation as a result of direct surgical trauma, such as incisions; Sepracoat is the only product designed to reduce adhesion formation as a result of indirect trauma, such as tissue drying due to exposure.
GENZYME'S SEPRAFILM RECOMMENDED FOR U.S. APPROVAL
Adhesions in patients treated with Sepracoat were, on average, 38 percent less severe and 42 percent less extensive than those in the control group.
GENZYME'S SEPRACOAT 'SAFE AND EFFECTIVE' IN REDUCING ADHESIONS IN CLINICAL STUDY
Genzyme is seeking approval to market Sepracoat to reduce postoperative adhesion formation that results from indirect surgical trauma in "abdominal, pelvic, and cardio-thoracic surgical procedures.
GENZYME SUBMITS PREMARKET APPROVAL APPLICATION FOR SEPRACOAT(TM)
Medical browser ?
Full browser ?